3.88

2.37% 0.09

Oramed Pharmaceuticals Inc (ORMP)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Oramed Pharmaceuticals Inc stock is traded at $3.88, with a volume of 148.93K. It is up +2.37% in the last 24 hours and down -9.56% over the past month. Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.

Previous Close:

$3.79

Open:

$3.86

24h Volume:

148.93K

Relative Volume:

0.95

Market Cap:

$158.79M

Revenue:

$2.00M

Net Income/Loss:

$109.16M

P/E Ratio:

1.5018

EPS:

2.5835

Net Cash Flow:

$-9.11M

1W Performance:

+2.11%

1M Performance:

-9.56%

6M Performance:

+30.20%

1Y Performance:

+80.47%

1-Day Range:

$3.805

$3.89

1-Week Range:

$3.76

$3.93

52-Week Range:

$1.975

$5.01

Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile

Name

Oramed Pharmaceuticals Inc

Sector

Healthcare (1104)

Industry

Biotechnology (617)

Phone

646-844-1164

Address

1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY

Employee

Twitter

@OramedPharma

Next Earnings Date

2026-08-13

Latest SEC Filings

ORMP's Discussions on Twitter

Compare ORMP vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ORMP Oramed Pharmaceuticals Inc	3.88	158.79M	2.00M	109.16M	-9.11M	2.5835
VRTX Vertex Pharmaceuticals Inc	451.63	114.63B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	609.94	63.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.72	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	278.09	37.13B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	162.99	34.65B	742.00K	-1.37B	-1.07B	-7.0731

Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-12-23	Downgrade	Canaccord Genuity	Buy → Hold
Feb-18-22	Initiated	Cantor Fitzgerald	Overweight
Apr-20-21	Initiated	Canaccord Genuity	Buy
Feb-09-21	Initiated	National Securities	Buy
Dec-03-20	Initiated	Alliance Global Partners	Buy
Mar-11-20	Initiated	Aegis Capital	Buy
Sep-11-19	Initiated	Ladenburg Thalmann	Buy
Dec-11-17	Resumed	B. Riley FBR, Inc.	Buy
May-26-16	Reiterated	FBR Capital	Outperform
Dec-01-15	Reiterated	H.C. Wainwright	Buy
Nov-19-15	Initiated	FBR Capital	Outperform
Apr-13-15	Resumed	MLV & Co	Buy
Jan-30-14	Reiterated	Aegis Capital	Buy
Jan-08-14	Reiterated	Aegis Capital	Buy
Jan-08-14	Initiated	MLV & Co	Buy
Dec-03-13	Initiated	Aegis Capital	Buy

View All

Oramed Pharmaceuticals Inc Stock (ORMP) Latest News

Jun 18, 2026

Daily Brief United States: Tesla , Adobe Systems, Nine Energy Service , Oramed Pharmaceuticals , Olin Corp, Earth Science Tech, Kardigan, Generac Holdings, General Motors, Nucor Corp and more - Smartkarma

Jun 18, 2026

ORMP: View Inclusion in Russell Indexes as Positive That Could Raise Awareness in Investment Community - Yahoo Finance

Jun 18, 2026